Patients with malignancy are less likely to undergo stenting, receive drug-eluting stents, receive newer generation P2Y12 inhibitors (ticagrelor or prasugrel), and receive standard of care medications (beta-blockers, statins, or angiotensin-converting enzyme inhibitors) compared with those without cancer (193,194). This evidence concerns the gene P2RY12 and cancer.